Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
First Claim
Patent Images
1. A method for preventing and/or treating Alzheimer'"'"'s disease and/or cerebral amyloid angiopathy in a patient at risk for developing or diagnosed with the same, the method comprising:
- administering to the patient an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ) for a first enzyme enhancement period;
not administering the AdDNJ for a substrate turnover period; and
thenadministering to the patient an effective amount of AdDNJ for a second enzyme enhancement period.
3 Assignments
0 Petitions
Accused Products
Abstract
Described herein are dosing regimens and kits for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer'"'"'s disease (AD) and/or cerebral amyloid angiopathy (CAA).
2 Citations
26 Claims
-
1. A method for preventing and/or treating Alzheimer'"'"'s disease and/or cerebral amyloid angiopathy in a patient at risk for developing or diagnosed with the same, the method comprising:
-
administering to the patient an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ) for a first enzyme enhancement period; not administering the AdDNJ for a substrate turnover period; and
thenadministering to the patient an effective amount of AdDNJ for a second enzyme enhancement period. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A kit comprising:
-
one or more dosage forms comprising an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ); and instructions for; administering the dosage forms for a first enzyme enhancement period; not administering the dosage forms for a substrate turnover period; and
thenadministering the dosage forms for a second enzyme enhancement period. - View Dependent Claims (20, 21, 22)
-
-
23. A kit comprising:
-
one or more active dosage forms comprising an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ); one or more inactive dosage forms that do not comprise an effective amount of AdDNJ; and instructions for; administering the active dosage forms for a first enzyme enhancement period; administering the inactive dosage forms for a substrate turnover period; and
thenadministering the active dosage forms for a second enzyme enhancement period. - View Dependent Claims (24, 25, 26)
-
Specification